Skip to main content

Advertisement

Table 1 Demographic and disease characteristics of the study population

From: Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

  All patients (number = 291) RA on MTX (number = 50) RA on anti-TNF monotherapy (number = 38) RA on anti-TNF + MTX (number = 53) RA on abatacept (number = 5) RA on rituximab (number = 10) RA on tocilizumab (number = 2) SpA on anti-TNF monotherapy (number = 41) SpA on anti-TNF + MTX (number = 51) SpA on NSAIDs/ analgesics controls (number = 41)
Age (years) mean (range) 57 (23 to 87) 62.3 (26 to 87) 62.4 (32 to 86) 61.1 (41 to 83) 55.2 (43 to 66) 62.3 (43 to 79) 63.5 (55 to 72) 49.0 (2 to 69) 52.6 (26 to 71) 52.2 (23 to 72)
Gender (% female) 64 78 84 80 86 80 100 37 51 51
Disease duration (years) mean (range) 16.0 (1 to 55) 12.5 (1 to 41) 21.1 (3 to 46) 18.2 (2 to 48) 12.4 (6 to 24) 22.3 (5 to 55) 21.5 (15 to 28) 16.6 (1 to 36) 13.1 (1 to 42) 14.3 (1 to 37)
RF positive (%) 43 76 87 76 100 80 100 ----- ----- ----
Anti-CCP positive (%) 43 82 74 83 80 80 50 ------ ----- ……
HLA-B27 positve (%) 22.3 ----- ------ ----- ------ ------- ------ 56 28 68
  1. MTX, methotrexate; NSAIDS, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SpA, spondylarthropathy.